clinical trial · NCT07230977
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.·phase1·recruiting·n = 280
Advanced Solid TumorsGenSci139
brief summary
This is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with locally advanced or metastatic solid tumors, as well as identity MTD (if any) and RDE. The Part 2 study is to further evaluate the preliminary anti-tumor activities, safety, PK profile, immunogenicity and biomarker of GenSci139 at RDE dose levels with selected advanced cancers.
started
Nov 19, 2025
primary completion
Jul 7, 2028
completion
Jan 8, 2029
last updated
Dec 24, 2025
official title
A Phase I, Two-Part, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activities of GenSci139 in Patients With Locally Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol